A Structured Investigation into Functional Recovery in Type 1 Diabetes
SweetFreedom is building a 24-month, publication-grade pilot designed to test whether measurable functional recovery is biologically achievable beyond the honeymoon window in established Type 1 Diabetes.
We are seeking clinical collaborators who are open to disciplined, mechanism-driven investigation.
This is not an alternative medicine initiative.
This is not an anti-endocrinology position.
This is a structured hypothesis test built on emerging signals across immunology, metabolism, microbiome science, and beta-cell biology.
The Scientific Framing
The dominant model of Type 1 Diabetes focuses on autoimmune-mediated beta-cell destruction.
Yet converging research suggests a more complex landscape:
• Beta cells under inflammatory stress actively signal immune recruitment
• Gut microbiome shifts frequently precede seroconversion
• Persistent low-grade viral signatures may sustain islet stress
• Alpha–beta signaling imbalance affects islet stability
• Regeneration pathways appear biologically inducible under certain conditions
These signals remain largely investigated in isolation.
SweetFreedom’s objective is to test whether sequencing systemic stress reduction and biological stabilization can create conditions permissive to functional recovery.
The 24-Month Pilot Framework
Population
• 8–10 adolescents and young adults (ages 16–30)
• ≥2 years since diagnosis
• Beyond the honeymoon window
• Including participants with minimal residual C-peptide
Primary Endpoint
Stimulated C-peptide (MMTT) at baseline, 12 months, and 24 months.
Secondary Measures
• Insulin requirement trends
• CGM-derived stability metrics
• Longitudinal microbiome profiling
• Inflammatory and immune biomarkers
• Hormonal signaling markers within the islet axis
Design Architecture
Biomarker-Gated Progression
Phase transitions are triggered by measurable biological shifts rather than fixed timelines.
Conventional Care Maintained
All participants continue standard insulin therapy under endocrinology supervision.
Independent Oversight
Principal Investigator (Endocrinology), biostatistical supervision, and structured safety governance.
The goal is not short-term modulation.
The goal is to test whether restoration is biologically measurable.
What We Are Looking For in a Clinical Partner
We are seeking a collaborator who:
• Is comfortable testing bold but biologically grounded hypotheses
• Values disciplined protocol structure over ideological positioning
• Understands the distinction between speculation and structured inquiry
• Is willing to operate within independent governance and publication standards
This initiative requires courage — but it also requires rigor.
What This Is Not
• Not a replacement for standard care
• Not a commercialization effort
• Not a claim of cure
• Not a bypass of regulatory oversight
The ambition is high.
The discipline must be higher.
Why Engage
If measurable functional recovery is observed beyond the honeymoon window — even partially — the implications would extend across immunology, regeneration science, and long-term metabolic management.
If no signal is observed, the field gains clarity.
Either outcome advances understanding.
Next Step
If you are an endocrinologist, clinical researcher, or institutional leader interested in reviewing the full scientific dossier and pilot architecture, we invite a structured conversation.
We are building this with governance, not ideology.
[ Request a Clinical Discussion ]
